Heron Therapeutics’ (HRTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Heron Therapeutics (NASDAQ:HRTX) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $6.00 target price on the biotechnology company’s stock.

A number of other analysts have also recently commented on the company. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Stock Up 9.4%

NASDAQ:HRTX opened at $1.39 on Friday. The company has a debt-to-equity ratio of 19.89, a current ratio of 2.56 and a quick ratio of 1.78. The firm’s 50-day moving average price is $1.22 and its 200-day moving average price is $1.42. The company has a market capitalization of $254.87 million, a PE ratio of -15.44 and a beta of 1.28. Heron Therapeutics has a 1-year low of $1.00 and a 1-year high of $2.68.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The company had revenue of $38.21 million for the quarter, compared to analyst estimates of $39.03 million. On average, equities analysts predict that Heron Therapeutics will post -0.13 EPS for the current fiscal year.

Institutional Trading of Heron Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Clearline Capital LP grew its stake in shares of Heron Therapeutics by 1,033.1% during the 3rd quarter. Clearline Capital LP now owns 9,712,527 shares of the biotechnology company’s stock valued at $12,238,000 after purchasing an additional 8,855,361 shares during the period. Baker BROS. Advisors LP purchased a new position in shares of Heron Therapeutics in the third quarter worth approximately $5,357,000. Citigroup Inc. grew its position in Heron Therapeutics by 4,666.9% during the third quarter. Citigroup Inc. now owns 2,476,529 shares of the biotechnology company’s stock valued at $3,120,000 after buying an additional 2,424,576 shares during the period. Rubric Capital Management LP grew its position in Heron Therapeutics by 8.9% during the third quarter. Rubric Capital Management LP now owns 29,100,728 shares of the biotechnology company’s stock valued at $36,667,000 after buying an additional 2,387,225 shares during the period. Finally, Velan Capital Investment Management LP increased its holdings in Heron Therapeutics by 25.3% during the third quarter. Velan Capital Investment Management LP now owns 8,753,290 shares of the biotechnology company’s stock valued at $11,029,000 after buying an additional 1,766,546 shares during the last quarter. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics News Roundup

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Preliminary results: Heron reported preliminary Q4 net revenue of approximately $40.5M and full‑year 2025 net revenue of ~$154.9M, slightly above consensus — a near-term fundamental catalyst. GlobeNewswire Release
• Positive Sentiment: Product momentum: ZYNRELEF® drove Q4 growth (≈$12.5M, up ~35% Q/Q); CINVANTI and APONVIE also contributed, signaling improving commercial traction in acute care and oncology portfolios. Quiver Quant
• Positive Sentiment: Analyst support: HC Wainwright reaffirmed a “buy” and set a $6.00 price target, signaling strong upside expectations that can attract momentum buyers. Benzinga
• Neutral Sentiment: Market coverage: Multiple outlets reported the beat and product growth, amplifying visibility and short‑term trading interest but not adding new fundamental data beyond the company release. Investing.com
• Neutral Sentiment: Revenue guidance alignment: The company updated Q4 and FY 2025 revenue guidance to the preliminary figures ($40.5M Q4; $154.9M FY), so the market reaction reflects confirmation rather than a surprise revision.
• Negative Sentiment: Preliminary/unaudited figures: Results are unaudited and subject to final accounting adjustments — investors should watch the audited release and any revisions. GlobeNewswire Release
• Negative Sentiment: Concentration risk & prior misses: Revenue remains concentrated in a few products and the company recently missed EPS estimates (Nov 2025), which could temper longer-term sentiment if margin/earnings improvements don’t follow revenue gains.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.